穿孔素1(PRF1)重组蛋白
Recombinant Perforin 1 (PRF1)
FLH2; HPLH2; P1; PFP; Pore Forming Protein; Cytolysin; Lymphocyte pore-forming protein
- 编号RPB317Ra01
- 物种Rattus norvegicus (Rat,大鼠) 相同的名称,不同的物种。
- 来源原核表达
- 宿主E.coli
- 内毒素水平<1.0EU/µg(LAL法测定)
- 亚细胞定位Cytoplasmic granule lumen.Secreted.Cell membrane; Multi-pass membrane protein. Endosome lum
- 预测分子量29.7kDa
- 实际分子量33kDa(差异分析请参阅说明书)
- 片段与标签Ala120~Asp353 (Accession # P35763) with
- 缓冲液成份磷酸盐缓冲液(pH7.4,含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.)
- 性状冻干粉
- 纯度> 95%
- 等电点6.3
-
应用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白,请参见活性蛋白。 - 下载 英文说明书 中文说明书
- 规格 10µg50µg 200µg 1mg 5mg
- 价格 ¥ 1128 ¥ 2820 ¥ 5640 ¥ 16920 ¥ 42300
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
序列
用法
PBS或其它。
储存
避免反复冻融。2-8°C不超过一个月,-80°C不超过12个月。
稳定性
热稳定性以损失率显示。损失率是由加速降解试验决定,具体方法如下:在37°C孵育48小时,没有显著的降解或者沉淀产生。保质期内,在适当的条件下存储,损失率低于5%。
增值服务
相关产品
编号 | 适用物种:Rattus norvegicus (Rat,大鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPB317Ra01 | 穿孔素1(PRF1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
APB317Ra01 | 穿孔素1(PRF1)活性蛋白 | Cell culture; Activity Assays. |
PAB317Ra01 | 穿孔素1(PRF1)多克隆抗体 | WB; IHC; ICC; IP. |
MAB317Ra21 | 穿孔素1(PRF1)单克隆抗体 | WB; IHC; ICC; IP. |
SEB317Ra | 穿孔素1(PRF1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
LMB317Ra | 穿孔素1(PRF1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
Diagnostic Microbiology and Infectious Disease | Granzyme B as a diagnostic marker of tuberculosis in patients with and without HIV coinfection [Pubmed:26915636] |
FASEB JOURNAL | The immunoregulatory effects of CD8 T-cell–derived perforin on diet-induced nonalcoholic steatohepatitis [Pubmed: 30951375] |
Theranostics | A novel Granzyme B nanoparticle delivery system simulates immune cell functions for suppression of solid tumors [Pubmed: 31695790] |
Mol Immunol | CD317 mediates immunocytolysis resistance by RICH2/cytoskeleton-dependent membrane protection [Pubmed: 33223223] |
INVESTIGATIONAL NEW DRUGS | Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors [Pubmed: 32772342] |
Am J Transl Res | Combined treatment with epigenetic agents enhances anti-tumor activity of T cells by upregulating the ACRBP expression in hepatocellular carcinoma [34377237] |
Nat Biomed Eng | Cancer-cell stiffening via cholesterol depletion enhances adoptive T-cell immunotherapy [34873307] |
J Exp Med | Single-cell immune profiling reveals functional diversity of T cells in tuberculous pleural effusion [Pubmed:35061012] |
留言咨询